Christopher Haqq - 16 Jul 2026 Form 4 Insider Report for Elicio Therapeutics, Inc. (ELTX)

Reporting relationship: Executive Vice President, Head of R&D and Chief Medical Officer
Issuer ticker: ELTX
Reported as of: 16 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jul 2026, 16:14:39 UTC
Prior SEC filing: 03 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Haqq

Key filing fact

Christopher Haqq filed Form 4 for Elicio Therapeutics, Inc. (ELTX) on 17 Jul 2026.

Key facts

This page summarizes Christopher Haqq's Form 4 filing for Elicio Therapeutics, Inc. (ELTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Jul 2026, 16:14.

Change

Previous filing in this sequence was filed on 03 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001612095 Primary reporting owner

Haqq Christopher

Relationship: Executive Vice President, Head of R&D and Chief Medical Officer
Address: C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON
Signature: /s/ Christopher Haqq
Signature date: 17 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +64,643
Change %
Price: $0.000000^*
Shares after: 64,643
Date: 16 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 64,643
Exercise price: $3.20
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC remarks

Executive Vice President, Head of R&D and Chief Medical Officer